Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2013 1
2014 1
2017 1
2020 1
2021 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors.
Decary S, Berne PF, Nicolazzi C, Lefebvre AM, Dabdoubi T, Cameron B, Rival P, Devaud C, Prades C, Bouchard H, Cassé A, Henry C, Amara C, Brillac C, Ferrari P, Maçon L, Lacoste E, Combeau C, Beys E, Naimi S, García-Echeverría C, Mayaux JF, Blanc V. Decary S, et al. Among authors: amara c. Clin Cancer Res. 2020 Dec 15;26(24):6589-6599. doi: 10.1158/1078-0432.CCR-19-4051. Epub 2020 Oct 12. Clin Cancer Res. 2020. PMID: 33046521
Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123.
Gauthier L, Virone-Oddos A, Beninga J, Rossi B, Nicolazzi C, Amara C, Blanchard-Alvarez A, Gourdin N, Courta J, Basset A, Agnel M, Guillot F, Grondin G, Bonnevaux H, Bauchet AL, Morel A, Morel Y, Chiron M, Vivier E. Gauthier L, et al. Among authors: amara c. Nat Biotechnol. 2023 Sep;41(9):1296-1306. doi: 10.1038/s41587-022-01626-2. Epub 2023 Jan 12. Nat Biotechnol. 2023. PMID: 36635380 Free PMC article.
In vivo testing of drug-linker stability.
Abecassis PY, Amara C. Abecassis PY, et al. Among authors: amara c. Methods Mol Biol. 2013;1045:101-16. doi: 10.1007/978-1-62703-541-5_6. Methods Mol Biol. 2013. PMID: 23913143
Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment.
Bonnevaux H, Guerif S, Albrecht J, Jouannot E, De Gallier T, Beil C, Lange C, Leuschner WD, Schneider M, Lemoine C, Caron A, Amara C, Barrière C, Siavellis J, Bardet V, Luna E, Agrawal P, Drake DR, Rao E, Wonerow P, Carrez C, Blanc V, Hsu K, Wiederschain D, Fraenkel PG, Virone-Oddos A. Bonnevaux H, et al. Among authors: amara c. Oncoimmunology. 2021 Aug 31;10(1):1945803. doi: 10.1080/2162402X.2021.1945803. eCollection 2021. Oncoimmunology. 2021. PMID: 34484869 Free PMC article.
Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers.
Certal V, Carry JC, Halley F, Virone-Oddos A, Thompson F, Filoche-Rommé B, El-Ahmad Y, Karlsson A, Charrier V, Delorme C, Rak A, Abecassis PY, Amara C, Vincent L, Bonnevaux H, Nicolas JP, Mathieu M, Bertrand T, Marquette JP, Michot N, Benard T, Perrin MA, Lemaitre O, Guerif S, Perron S, Monget S, Gruss-Leleu F, Doerflinger G, Guizani H, Brollo M, Delbarre L, Bertin L, Richepin P, Loyau V, Garcia-Echeverria C, Lengauer C, Schio L. Certal V, et al. Among authors: amara c. J Med Chem. 2014 Feb 13;57(3):903-20. doi: 10.1021/jm401642q. Epub 2014 Jan 15. J Med Chem. 2014. PMID: 24387221
Design of potent and selective GSK3beta inhibitors with acceptable safety profile and pharmacokinetics.
Lesuisse D, Tiraboschi G, Krick A, Abecassis PY, Dutruc-Rosset G, Babin D, Halley F, Châtreau F, Lachaud S, Chevalier A, Quarteronet D, Burgevin MC, Amara C, Bertrand P, Rooney T. Lesuisse D, et al. Among authors: amara c. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2344-9. doi: 10.1016/j.bmcl.2010.01.132. Epub 2010 Feb 2. Bioorg Med Chem Lett. 2010. PMID: 20189807